Obesity prevalence stands at nearly 23%, contributing to 41% of demand growth for weight management applications
In the Phase 2 NEJM trial (2023), participants on 12 mg lost an average of 24.2% of body weight at 48 weeks
Not only is this helpful in controlling type 2 diabetes, but it also induces natural weight loss and has other positive health benefits, including decreased: Blood pressure Cholesterol Inflammation triglycerides Who Is a Good Candidate for Semaglutide
Keeping a record of visual disturbances through systematic self-monitoring helps healthcare providers differentiate between medication-related effects and unrelated eye problems, allowing for appropriate intervention strategies
Research has shown that even non-GLP-1RA agents have appetite-suppressing effects and can improve obesity (Newgard et al., 2009) or compare insulin-sensitive and insulin-resistant individuals (Tai et al., 2010), and are associated with the persistence of childhood obesity (Wu et al., 2024)